Spero Therapeutics to Present at March Investor Conferences
March 01 2019 - 7:30AM
Spero Therapeutics, Inc. (Nasdaq:SPRO), a multi-asset
clinical-stage biopharmaceutical company focused on identifying,
developing and commercializing treatments in high unmet need areas
involving multi-drug resistant bacterial infections, today
announced that Ankit Mahadevia, M.D., President and Chief
Executive Officer of Spero Therapeutics, will provide a
corporate update at the following investor conferences in March
2019:
- Cowen and Company 39th Annual Health Care
Conference on Tuesday, March 12, 2019 at 12:00 PM
ET in Boston, Massachusetts
- Oppenheimer 29th Annual Healthcare
Conference on Wednesday, March 20, 2019 at 10:20 AM
ET in New York, New York
Webcasts of the presentations may be accessed
through Spero Therapeutics’ website
(www.sperotherapeutics.com) on the “Events and
Presentations” page under the “Investors and Media” tab.
Replays of the presentations will be archived on the website for 90
days following the conclusion of each event.
About Spero
Therapeutics
Spero Therapeutics, Inc. is a multi-asset,
clinical-stage biopharmaceutical company focused on identifying,
developing and commercializing novel treatments for
multidrug-resistant (MDR) bacterial infections.
Spero’s lead product candidate, SPR994, is
designed to be the first oral carbapenem-class antibiotic for use
in adults to treat MDR Gram-negative infections. Spero has
begun start-up activities for the ADAPT-PO Phase 3 clinical trial
of SPR994 for the treatment of complicated urinary tract infections
and anticipates opening trial sites to support study enrollment in
the first quarter of 2019.
Spero is also advancing SPR720, its novel oral
therapy product candidate designed for the treatment of
non-tuberculous mycobacterial (NTM) infections. In January
2019, Spero initiated a Phase 1 clinical trial of SPR720 in healthy
subjects and expects top-line data from this trial in the second
half of 2019.
Spero also has a platform technology known as
its Potentiator Platform that it believes will enable it to develop
drugs that will expand the spectrum and potency of existing
antibiotics, including formerly inactive antibiotics, against
Gram-negative bacteria. Spero’s lead product candidates generated
from its Potentiator Platform are two IV-administered agents,
SPR741 and SPR206, designed to treat MDR Gram-negative infections
in the hospital setting. In December 2018, Spero initiated a Phase
1 clinical trial of SPR206 in healthy subjects and expects top-line
data from this trial in the second half of 2019.
For more information,
visit https://sperotherapeutics.com.
Forward-Looking Statements
This press release may contain forward-looking
statements. These statements include, but are not limited to,
statements about Spero’s expectation that positive results from a
single pivotal Phase 3 clinical trial of SPR994 and ancillary
supportive studies to be conducted in parallel with the planned
Phase 3 trial will support the approval of SPR994; the initiation,
timing, progress and results of Spero’s preclinical studies and
clinical trials and its research and development programs,
including the anticipated timing of the opening of sites to support
enrollment into the planned pivotal Phase 3 clinical trial of
SPR994; statements regarding management’s assessment of the results
of such preclinical studies and clinical trials; the timing of
clinical data, including the availability of top-line data from the
Phase 1 clinical trial of SPR206 and the Phase 1 clinical trial of
SPR720; and Spero’s cash forecast and anticipated expenses, the
sufficiency of its cash resources and the availability of
additional non-dilutive funding from governmental agencies beyond
any initially funded awards. In some cases, forward-looking
statements can be identified by terms such as “may,” “will,”
“should,” “expect,” “plan,” “aim,” “anticipate,” “could,” “intent,”
“target,” “project,” “contemplate,” “believe,” “estimate,”
“predict,” “potential” or “continue” or the negative of these terms
or other similar expressions. Actual results may differ materially
from those indicated by such forward-looking statements as a result
of various important factors, including whether
the FDA will accept a single pivotal study for approval
of SPR994; whether results obtained in preclinical studies and
clinical trials will be indicative of results obtained in future
clinical trials; whether Spero’s product candidates will advance
through the preclinical development and clinical trial process on a
timely basis, or at all, taking into account the effects of
possible regulatory delays, slower than anticipated patient
enrollment, manufacturing challenges, clinical trial design and
clinical outcomes; whether the results of such trials will warrant
submission for approval from the U.S. Food and Drug
Administration or equivalent foreign regulatory agencies;
whether Spero’s cash resources will be sufficient to fund its
continuing operations for the periods and/or trials anticipated;
and other factors discussed in the “Risk Factors” set forth in
filings that Spero periodically makes with the U.S. Securities
Exchange Commission. The forward-looking statements included in
this press release represent Spero’s views as of the date of this
press release. Spero anticipates that subsequent events and
developments will cause its views to change. However, while Spero
may elect to update these forward-looking statements at some point
in the future, it specifically disclaims any obligation to do so.
These forward-looking statements should not be relied upon as
representing Spero’s views as of any date subsequent to the date of
this press release.
Spero Investor and Media Contact: Sharon Klahre
Director, Investor Relations 857-242-1547
IR@sperotherapeutics.com
Spero Therapeutics (NASDAQ:SPRO)
Historical Stock Chart
From Apr 2024 to May 2024
Spero Therapeutics (NASDAQ:SPRO)
Historical Stock Chart
From May 2023 to May 2024